ReviewCurrent heart failure reports2015
Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.
Review in Current heart failure reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy.Frontiers in pharmacology · 2025Review
- Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies.Diagnostics (Basel, Switzerland) · 2023Review
- Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer.Scientific reports · 2021Article
- Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice.Breast (Edinburgh, Scotland) · 2020Review
- African Vegetables (Oxidative medicine and cellular longevity · 2020Article
- Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.Frontiers in cardiovascular medicine · 2020Article
- Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity.Frontiers in pharmacology · 2020Article
- Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity.Current cardiology reports · 2018Review
- Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.Scientific reports · 2017Article
- Current views on anthracycline cardiotoxicity.Heart failure reviews · 2016Review
- Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy.Biomarkers in cancer · 2016Review
- S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers.PloS one · 2015Article
- Cardiac Toxicity and Anthracyclines: Mechanism, Interventions, and the Trouble With Troponin.Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The success achieved in advances in cancer therapy has been marred by development of cardiotoxicity, which causes significant morbidity and mortality. This has led to the development of surveillance protocols for cardiotoxicity utilizing multimodality imaging techniques and investigation of various drugs to treat and prevent cardiotoxicity in this subset of patients. Cardiac biomarkers hold important diagnostic and prognostic value in various cardiac diseases. In this review, we discuss the use of biomarkers in patients receiving chemotherapy, highlighting data behind the use of troponin, B-type natriuretic peptide, and myeloperoxidase. We also discuss the use of dexrazoxane, angiotensin-converting enzyme inhibitors, and beta blockers in the treatment and prevention of chemotherapy-induced cardiotoxicity. Cardiac biomarkers may serve an important role in selecting patients that are at high risk of cardiotoxicity and can potentially be used to guide the administration of drugs to treat and prevent cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.